Evi-1 is a transcription factor that is implicated in leukemic transformation of hematopoietic cells. Two distinct alternative forms, Evi-1a and Evi-1c, are generated from the EVI-1 gene. Whereas Evi-1a is widely recognized as an oncoprotein, a role for Evi-1c, which has an additional PR domain in the amino-terminus of Evi-1a, in leukemogenesis, has not been elucidated thus far. Aberrant oligomerization of transcription factors has recently emerged as a prevalent mechanism for activating their oncogenic potential in hematopoietic malignancies. Here, to study the mechanisms that underlie Evi-1-mediated oncogenesis, we investigated formation of oligomeric complexes by the Evi-1 proteins. We show that Evi-1a forms homo-oligomers, whereas Evi-1c exclusively exists as a monomer in mammalian cells. Remarkably, Evi-1c has lost the ability to interact with CtBP, a transcriptional corepressor that associates with Evi-1a. As a consequence, the ability of Evi-1c to repress transforming growth factor-b (TGF-b) signaling is significantly abrogated. These results identify a novel function of a PR domain to regulate oligomerization of transcription factors and suggest that homo-oligomerization may play a critical role in corepressor recruitment by the Evi-1 proteins. In addition, we found that the chimeric oncoprotein acute myelocytic leukemia (AML)1-Evi-1, generated in t(3;21) leukemia, also forms homo-oligomers and hetero-oligomers with Evi-1a, while it did not interact with Evi-1c. Consistent with the results, repression of TGF-b by AML1-Evi-1 was significantly enhanced by Evi-1a, whereas it was hardly affected by the presence of Evi-1c. These results suggest that oligomerization may contribute to the oncogenic potential of Evi-1-containing proteins.
Introduction
The EVI-1 gene encodes a zinc-finger transcription factor closely associated with the development of human myeloid malignancies. The alternative forms generated from the EVI-1 gene include two distinct proteins, Evi1a and Evi-1c, with the latter also called myelodysplastic syndrome (MDS)1-Evi-1 (Hirai, 1999) . Evi-1a is highly expressed in cases with human myeloid leukemia or MDS as a consequence of chromosomal rearrangements involving 3q26, to which EVI-1 is mapped (Ogawa et al., 1996a-c) . Elevated expression of Evi-1a is also observed without 3q26 abnormalities. Recent studies have shown that elevated expression of Evi-1a in acute myelocytic leukemia (AML), which occurs in approximately 10% of the cases, is associated with unfavorable outcomes (Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2003; Valk et al., 2004) . These facts strongly suggest a critical role for Evi-1a in human leukemogenesis. Previous studies revealed that Evi-1a possesses diverse functions as an oncoprotein Kurokawa et al., 2000) . Among those studies is our demonstration that Evi-1a antagonizes growth-inhibitory effects of transforming growth factor-b (TGF-b) by interacting with Smad3 (Kurokawa et al., 1998b) . Evi-1a blocks granulocytic differentiation of 32Dcl3 cells, a murine myeloid cell line (Morishita et al., 1992) and thought to possess the abilities to promote growth and block differentiation in some types of cells. Furthermore, Evi-1a interacts with corepressor CtBP and this interaction contributes to Evi-1-mediated repression of TGF-b signaling Palmer et al., 2001) . In spite of an established role for Evi-1a in human leukemogenesis, a function of Evi-1c has been poorly understood thus far. The expression level of Evi-1c in myeloid malignancies is known to widely vary depending on cases and does not predict prognoses, which contrasts with a clinical significance of Evi-1a. As for biochemical functions, it is known that Evi-1c cannot efficiently repress TGF-b signaling when introduced into 32Dcl3 cells and has no effect on their granulocytic differentiation (Sood et al., 1999) . Available evidence suggests that Evi-1c on its own does not exert an oncogenic effect on hematopoietic cells. Structurally in Evi-1c, amino (N)-terminally to the Evi-1a moiety lies a 188 amino-acid region of a homology called a PR domain. A PR domain was identified as a common motif shared by the human retinoblastoma-proteinbinding protein RIZ1 and the human transcriptional repressor PRDI-BF1 and has been found in at least 17 kinds of diverse proteins to date (Buyse et al., 1995; Huang, 1994 Huang, , 2002 . A large body of evidence suggests that PR domain proteins are involved in the regulation of cellular growth as well as tumorigenesis. Intriguingly, for each of these PR domain proteins does the alternative form which lacks a PR domain exist and inactivation of PR-containing forms and/or activation of PR-absent forms are observed in a variety of cancer cells, suggesting a functional antagonism in which, the PR-containing forms contribute to tumor suppression, while the PR-absent forms are oncogenic (Jiang and Huang, 2000) .
One of leukemia-associated fusion proteins that contain Evi-1 is AML1-Evi-1, which is generated in the t(3;21) translocation seen in the blastic crisis of chronic myelogenous leukemia or MDS-derived leukemia. In AML1-Evi-1, the entire of Evi-1c except the first 12 amino acids fuses AML1, generating the AML1-Evi-1 fusion product . Many properties of Evi-1a are shared by AML1-Evi-1, including repression of TGF-b signaling, and association with CtBP (Tanaka et al., 1995; Kurokawa et al., 1998a; Izutsu et al., 2002) . AML1-Evi-1 exerts a wealth of diverse effects on cellular growth or differentiation, some of which can be attributed to the function of Evi-1a, including blockade of granulocytic differentiation of 32D cells (Kurokawa et al., 1998a) .
The pathogenesis of acute leukemias is closely associated with the actions of chimeric transcription factors (So and Cleary, 2004) . Recent studies revealed a recurring theme whereby forced oligomerization of chimeric transcription factors induced by the fusion partner confers aberrant transcriptional properties, which are hypothesized to be responsible for their oncogenic potential (Look, 1997; Mizuki et al., 2003) . In AML, the most prevalent chimeric transcriptional factors arise from mutations of retinoic acid receptor a (RARa), AML1 or mixed lineage leukemia (MLL) protein. Notably, all of these transcription factors were found in forming oligomers through the moiety of chimeric partners (Grignani et al., 1999; Minucci et al., 2000; Martin et al., 2003; So et al., 2003) .
In the present study, we demonstrate that Evi-1a forms homo-oligomers, whereas Evi-1c exclusively exists as a monomer. Remarkably, Evi-1c has lost the ability to interact with CtBP and failed to repress efficiently TGF-b signaling. We also found that AML1-Evi-1 forms homo-oligomers, indicating a close relationship between oligomer formation and CtBP binding. Furthermore, we revealed that AML1-Evi-1 forms hetero-oligomers with Evi-1a, while it did not interact with Evi-1c. Consistent with the results, repression of TGF-b by AML1-Evi-1 was significantly enhanced by Evi-1a, whereas it was hardly affected by the presence of Evi-1c. These results suggest that homo-oligomerization of Evi-1 plays a critical role for recruitment of CtBP, thus contributing to the oncogenic potential of the Evi-1 proteins.
Results

Evi-1a forms homo-oligomers but Evi-1c does not
We first examined whether Evi-1a is present as homooligomers in vivo. We expressed Flag-and T7-tagged versions of the Evi-1 proteins in COS7 cells, and then performed immunoprecipitation. As shown in Figure 1 , Flag-Evi-1a was co-immunoprecipitated with T7-Evi-1a (lane 2), while Flag-Evi-1c was never precipitated with T7-Evi-1c (lane 3). We also examined the intermolecular interaction between Evi-1a and Evi-1c. Evi-1a was never precipitated with Evi-1c and vice versa (Figure 1 , lanes 4 and 5). Thus, we concluded that Evi-1a forms homooligomers, while Evi-1c exists as a monomer. In addition, no heteromeric interaction was detected between Evi-1a and Evi-1c.
In order to confirm the oligomerization of Evi-1a, we sought to detect high molecular weight complexes formed by Evi-1a using a crosslinking analysis. HAtagged Evi-1a was expressed in 293T cells and whole-cell extracts were crosslinked with 2,2-dimethyl-2-silapentane-5-sulfonate (DSS). As shown in Figure 2a , most of the HA-Evi-1a protein was observed as a 150 kDa monomer in the absence of DSS (lane 2). On the other hand, in the presence of DSS, we detected a more slowly migrating band, which may represent a homo-dimeric form of Evi-1a (Figure 2a, lanes 3 and 4) . Only a small fraction of Evi-1a was observed as an oligomer complex, probably in part due to insufficient crosslinking efficiency of DSS. Then, we performed the crosslinking analysis of Evi-1c. For Evi-1c, however, we could not detect any slowly migrating band, but observed only a The PR domain regulates Evi-1 oligomerization E Nitta et al band that corresponds to a monomeric form ( Figure 2b ). These findings are consistent with the results of the co-immunoprecipitation assay and again indicate that Evi-1a forms homo-oligomers, whereas Evi-1c exists as a monomer.
To evaluate explicitly a role of the PR domain in oligomerization of Evi-1 proteins, we then constructed a mutant that lacks the PR domain of Evi-1c (Evi-1cDPR) ( Figure 2c ). As shown in Figure 2d , we revealed that this mutant recovered the ability to form a homo-oligomer. These results established the direct role of the PR domain as an inhibitor of Evi-1 self-oligomerization.
Next, we attempted to map the region of Evi-1a that is necessary for the oligomerization. First we examined the interaction of Evi-1a deletion mutants, which lack various functional domains, ZF1-7, Repression domain or ZF8-10 ( Figure 3a) . Both of ZF1-7 and ZF8-10 possess the ability to bind to DNA in vitro, while Repression domain is required for blockade of TGF-b signaling. All of these deletion mutants interacted with Evi-1a almost as efficiently as full-length Evi-1a ( Figure 3b ). These results suggest that none of these functional domains is strictly required for homooligomerization of Evi-1a. We also employed a mutant that lacks CtBP-binding domain (DCtBP) and a mutant that harbors specific amino-acid substitution in the consensus motif for CtBP binding (DL/AS), neither of which interacts with CtBP ) ( Figure 3a) . As shown in Figure 3b , both of these mutants can efficiently form homo-oligomers (lanes 5 and 6), indicating that self-association of Evi-1a is not dependent on CtBP. To search more extensively a region of Evi-1a involved in oligomer formation, we generated two types of deletion mutants, D(607-1051) and D(15-607) (Figure 3a) , and examined their interaction with full-length Evi-1a. Both of these mutants can form a complex with Evi-1a as efficiently as wild-type Evi-1a (Figure 3c , top, lanes 4-6). These results suggest that Evi-1a oligomerization may not be mediated through a small, restricted domain, but through a relatively wide stretch of multiple regions.
Intramolecular interaction between the PR domain and Evi-1a is absent.
Given that Evi-1c has lost the ability to oligomerize, it is tempting to speculate that a PR domain of Evi-1c may contribute to inhibition of oligomerization. Significant in this regard is the previous report that a PR domain of RIZ1 directly interacts with a carboxy (C)-terminal region of RIZ1 (Huang et al., 1998) . In light of structural similarity between RIZ1 and Evi-1c, it allowed us to speculate that PR domain-mediated intramolecular interaction in Evi-1c may prevent its homo-oligomerization. To test this, we produced a PR domain of Evi-1c fused to glutathione S-transferase (GST-PR) in Escherichia coli and purified. Then, a pulldown assay was performed using GST-PR with 293T cell extracts introduced each of the Evi-1 proteins. As shown in Figure 4 , neither Evi-1a nor Evi-1c bound to GST-PR (lanes 2 and 5). These results indicate that a PR The PR domain regulates Evi-1 oligomerization E Nitta et al domain derived from Evi-1c does not interact with the C-terminal region of Evi-1a or Evi-1c, unlike the case with RIZ1. Thus, the inability of Evi-1c to homo-oligomerize cannot be attributed to PR domainmediated intramolecular interaction but may depend on different regulation.
Evi-1c has lost the ability to associate with CtBP
To evaluate the functional consequence of oligomerization of the Evi-1 proteins, we attempted to explore the relevance of Evi-1c to interaction with CtBP and block of TGF-b signaling. As shown in Figure 5a , coimmunoprecipitation assay remarkably revealed that interaction between Evi-1c and CtBP was barely detectable, whereas interaction between Evi-1a and CtBP was explicitly recognized. Furthermore, deletion of the PR domain in Evi-1c (Evi-1cDPR) recovered the interaction with CtBP. These results indicate that Evi-1c cannot efficiently associate with CtBP unlike Evi-1a and that binding to CtBP is also regulated by the PR domain in the Evi-1 proteins.
Given the lack of interaction between Evi-1c and CtBP, we compared the ability of Evi-1c to repress TGF-b signaling with that of Evi-1a. Evi-1a repressed TGF-b-induced p3TP-Lux activation in HepG2 cells The PR domain regulates Evi-1 oligomerization E Nitta et al almost to control levels, as we previously reported (Figure 5b ) (Kurokawa et al., 1998b) . This repression was significantly abrogated when Evi-1c was transfected instead of Evi-1a. Sufficient repression of p3TP-Lux was elicited by Evi-1a even when Evi-1c was cotransfected, suggesting lack of a dominant-negative effect of Evi-1c on Evi-1a-mediated repression of TGF-b signaling. These results are consistent with our finding that Evi1c cannot efficiently recruit CtBP. We next tested the ability of Evi-1c to interact with Smad3, through which Evi-1a represses TGF-b signaling. As shown in Figure 6a , Evi-1c was coimmunoprecipitated with Smad3 (lane 4) as efficiently as Evi-1a (lane 2), indicating that binding to Smad3 was not impaired in Evi-1c. We also showed subcellular localization of Evi-1c (Figure 6b ). Evi-1c localizes predominantly in the nucleus and no differences existed in subcellular localization between Evi-1a and Evi-1c. These results suggest that the presence of the PR domain does not affect the ability of the Evi-1 proteins to interact with Smad3 or to localize in the nucleus.
AML1-Evi-1 has recovered the ability to form homooligomers
Our previous observation that chimeric oncoprotein AML1-Evi-1 can efficiently interact with CtBP through the identical region of the Evi-1 moiety and repress TGF-b signaling (Kurokawa et al., 1998a; Izutsu et al., 2002) encouraged us to examine whether AML1-Evi-1 forms homo-oligomers. As shown in Figure 7a , coimmunoprecipitation assay demonstrated that AML1-Evi-1 has recovered the ability to homo-oligomerize, as well as Evi-1a. These results also suggest a potential relevance of oligomerization to CtBP binding and oncogenic potential of the Evi-1 proteins. Furthermore, we revealed that AML1-Evi-1 forms hetero-oligomers with Evi-1a, while it did not interact with Evi-1c (Figure 7b) . Consistent with the results, repression of TGF-b by AML1-Evi-1 was significantly enhanced by Evi-1a, whereas it was hardly affected by the presence of Evi-1c (Figure 7c ). These results again suggest that oligomerization of Evi-1 proteins including AML1-Evi-1 are critical in repression of TGF-b signaling. Figure 4 Interaction between the PR domain and the Evi-1 proteins is absent. A pull-down assay to detect binding of the GST-PR domain to Evi-1a or Evi-1c (lanes 2 and 5). Inputs of whole-cell extracts from 293T cells introduced with Evi-1a or Evi-1c were shown (lanes 3 and 6). The gel was stained with Coomassie blue to demonstrate that the equivalent substrate was used in each reaction (lanes 7 and 8) The PR domain regulates Evi-1 oligomerization E Nitta et al
Discussion
In summary, our study indicates that Evi-1a, an oncogenic form of the EVI-1 gene product, forms a homo-oligomeric complex in mammalian cells. The addition of a PR domain in Evi-1c results in loss of the ability to homo-oligomerize. These data identify a novel function of a PR domain to inhibit oligomerization of hematopoietic transcription factors. In contrast to Evi-1a, Evi-1c failed to interact efficiently with CtBP. One of the functional consequences of this is the attenuated potential of Evi-1c to repress TGF-b signaling. Furthermore, fusion of Evi-1c to AML1 in AML1-Evi-1 restored homo-oligomerization, as well as interaction with CtBP, suggesting a potential relationship between homo-oligomerization and corepressor recruitment of the Evi-1 proteins.
The current study identified a novel function of the PR domain to inhibit oligomerization of Evi-1. Our data, however, did not define a specific sequence of Evi- lanes 2 and 4) . Interaction of Evi1-a and Evi-1c with Smad3 were both detectable (top). Expression of the Evi-1 proteins and Smad3 was monitored (middle and bottom). (b) Intracellular localization of Evi-1a and Evi-1c in COS7 cells was shown, using immunofluorescence staining. Nuclear stain was also shown Figure 7 (a) AML1-Evi-1 forms homo-oligomers. T7-tagged versions of AML1-Evi-1 were co-immunoprecipitated with the Flag-tagged versions of AML1-Evi-1 (top). Expression of T7-AML1-Evi-1 (middle) and Flag-AML1-Evi-1 (bottom) was shown. (b) Interaction between AML1-Evi-1 and Evi-1a or Evi-1c was examined. Hetero-oligomers of AML1-Evi-1 with Evi-1a were detected, while with Evi-1c was not seen. (c) Cooperation of AML1-Evi-1 and Evi-1a or Evi-1c in TGF-b repression. Additive effect was seen when AML1-Evi-1 and Evi-1a were concurrently transfected with p3TP-Lux reporter, whereas it was hardly seen when AML1-Evi-1 and Evi-1c were introduced
The PR domain regulates Evi-1 oligomerization E Nitta et al 1a, which contributes to homo-oligomer formation. A similar feature was recently disclosed by the 3D structural analysis on PLZF, one of the chimeric fusion partners of RARa, in which approximately one-quarter of the monomer surface area of PLZF is involved in its dimeric intermolecular contact (Ahmad et al., 1998) . In contrast to Evi-1a, we have demonstrated that the interaction between Evi-1c and CtBP is severely abrogated. Enforced dimerization of RARa chimeric proteins appears to enhance its affinity for transcriptional corepressors such as Sin3A, SMRT and Nco-R as bona fide RARa fusion proteins generated in human leukemia (Lin and Evans, 2000; Minucci et al., 2000) . Likewise, transcriptional repressor HIC1 (hypermethylated in cancer), which is a Kru¨ppel-like zinc-finger protein with an N-terminal BTB/POZ autonomous transcriptional repression domain, presumably requires dimerization through the BTB/POZ domain for the interaction with CtBP (Deltour et al., 2002) . A similar mechanism to these two proteins may be active, in which homo-oligomerization of Evi-1a results in the efficient recruitment of CtBP. Significant in this regard is our observation that AML1-Evi-1, which interacts with CtBP, can also form homo-oligomers. These findings also support a hypothesis that aberrant corepressor recruitment led by oligomerization is one of the important mechanisms for oncogenic transformation of hematopoietic cells by Evi-1-containing proteins.
In the current study, we have demonstrated that repression of TGF-b signaling by Evi-1c was significantly abrogated, as is consistent with the fact that the interaction with CtBP is required for full repression of TGF-b signaling by Evi-1a. These results actually differ from the previous report by the other group, in which Evi-1c showed a similar capacity to repress TGF-binduced 3TP-Luc activation (Sood et al., 1999) . The difference may in part be caused by the use of a different cell line in the transcriptional response assay. Although Evi-1c retains the ability to repress TGF-b signaling to a lesser extent than Evi-1a, the previous study showed that Evi-1a and Evi-1c exert different biological effects. When they are introduced to 32Dcl3 cells, a murine myeloid cell line, Evi-1a blocks G-CSF-induced granulocytic differentiation of the cells, while Evi-1c does not (Sood et al., 1999) . Moreover, our previous report showed that mutant protein that lacks CtBP binding ability of AML1-Evi-1 could not block this granulocytic differentiation of 32D cells, while wild-type AML1-Evi-1 blocked differentiation as Evi-1a does (Izutsu et al., 2002) . It would thus appear that impaired repression of TGF-b signaling in Evi-1c resulting from loss of CtBP binding can contribute to some biological effects of Evi-1. In addition, our result that Evi-1c did not possess a dominant interfering effect on repression of TGF-b signaling by Evi-1a seems to be in agreement with the clinical observation that high-level expression of Evi-1a predicts a poor prognosis in patients with AML regardless of Evi-1c expression level. These distinct properties of the Evi-1 proteins suggest a close relationship between homo-oligomer formation and the oncogenic activity of the Evi-1 proteins.
A PR domain has sequence homology with a SET domain, indicating that they might share some functional properties (Jiang and Huang, 2000) . A SET domain was noted as a region of 120-150 amino acids present in several proteins that are involved in chromatin-mediated gene regulation. The gene encoding MLL, one of the most well-known SET domain proteins is involved in more than three dozens of different chromosomal translocations found in hematological malignancies. As a consequence, in all of MLL fusion proteins with a wide variety of partner proteins that are expressed, a C-terminal SET domain of MLL was replaced with its fusion partner, partly or entirely (Dimartino and Cleary, 1999) . Furthermore, a large number of MLL fusion partners contain functional domains that mediate homo-oligomerization. Aberrant homo-oligomerization of SET domain chimeric proteins in MLL is reminiscent of AML1-Evi-1. Notably, recent studies demonstrate that homo-dimerization is necessary and sufficient for some of MLL fusion proteins to induce leukemia in a murine transplantation model (So et al., 2003) .
Taken together, our findings suggest that homooligomerization of the Evi-1 proteins may play an important role in their potential to induce hematological malignancies by regulating corepressor recruitment, although a precise role for oligomerization in Evi-1-mediated leukemogenesis should be addressed by future investigations.
Materials and methods
Cell culture
COS7, 293T and HepG2 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with penicillin, streptomycin and 10% fetal calf serum at 371C in a 5% CO 2 incubator. NIH3T3 cells were maintained in DMEM with 10% bovine serum.
cDNA constructs
Human Evi-1c cDNA was generated from AML1-EVI-1 cDNA by PCR, according to the previously reported sequence (Fears et al., 1996) . Human Evi-1a and Evi-1c cDNAs were inserted into the EcoRI site of pME18S (Takebe et al., 1988) or pCXN 2 (Niwa et al., 1991) . pME18S-AML1-EVI-1 was described elsewhere (Tanaka et al., 1995) . For tagging of Evi-1a, Evi-1c and AML1-Evi-1, the corresponding fragment was generated by PCR. Construction of Flag-tagged versions of Evi-1a mutants were made from FlagEvi-1a and the previously reported mutants Kurokawa et al., 1998b) .
Immunoprecipitation and Western blotting
COS7 cells were transfected by the diethylaminoethyl (DEAE)-dextran method as described previously and 293T cells were transfected by the calciumphosphate method. The cells were cultured for 48 h after transfection and were lysed in the TNE buffer (Lagna et al., 1996) . For immunoprecipitation, cell lysates were incubated with the anti-T7 (Novagen), the anti-Flag M2 monoclonal
The PR domain regulates Evi-1 oligomerization E Nitta et al antibody (Sigma), anti-CtBP mouse monoclonal antibody (Santa Cruz: E-12) or normal mouse IgG for 3 h at 41C. Then, the samples were incubated with protein-G-Sepharose (Amersham) for 1 h at 41C. The precipitates were washed five times with the TNE buffer and were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and analysis by Western blotting. Immunoblotting was performed with the anti-Flag antibody, the anti-T7 antibody or the anti-Evi-1 serum using the enhanced chemiluminescence system (Amersham).
Crosslinking Assay
To investigate the oligomerization of Evi-1a, crosslinking assay was performed as described previously (Kawabata et al., 1998) . The 293T cells were transfected with pCXN 2 -HA-Evi1a or pCXN 2 -HA-Evi-1c, and the cells were lysed in a buffer containing 20 mM HEPES, 150 mM NaCl, 0.5% Triton X-100, 1% aprotinin and 1 mM phenylmethylsulfonyl fluoride. Cell lysates were gently rotated at 41C for 30 min and the supernatants were incubated with various concentrations of DSS (Pierce Chemical Co.) for 15 min on ice. Samples were then subjected to immunoprecipitation using the anti-HA monoclonal antibody (12CA5), followed by immunoblotting using the same antibody.
GST pull-down assay
In all, 10 mg of bacterially produced GST fusion proteins were retrieved on Glutathione Sepharose 4B beads (Amersham) and incubated for 3 h at 41C in the lysates prepared from 293T cells transfected with Evi-1a or Evi-1c using the TNE buffer. Then, the beads were washed five times with the TNE buffer and subjected to SDS-PAGE followed by detection with immunoblotting by the anti-Evi-1 serum.
Transcriptional response assays
Analysis of luciferase activities was performed as described previously (Kurokawa et al., 1998b) . To determine the TGF-bmediated transcription response, HepG2 cells were transfected with the p3TP-Lux reporter plasmid along with the effector plasmid pME18S-Evi-1a, pME18S-Evi-1c or pME18S-AML1-Evi-1, and cells were treated with 200 pM TGF-b (Roche Diagnostics) for 24 h before harvesting. The cells were harvested 48 h after transfection and assayed for the luciferase activity by means of the luciferase assay system (Promega) and a luminometer (Lumat). The data were normalized to the b-galactosidase activity or the protein concentration.
Immunofluorescence stainings COS7 cells transfected with the expression plasmid for FlagEvi-1a or Flag-Evi-1c were fixed in 3.7% formaldehyde in phosphate-buffered saline. They were treated with the antiFlag M2 monoclonal antibody and then incubated with fluorescein isothiocyanate-conjugated donkey anti-mouse IgG (Jackson Immuno Research Laboratories Inc.), as secondary antibodies, as described previously (Kurokawa et al., 1998b; Imai et al., 2001) . Nuclear stain is performed using TO-PRO-3 (Invitrogen).
